Forecasting The Future: 4 Analyst Projections For ADMA Biologics
Portfolio Pulse from Benzinga Insights
Analyst ratings for ADMA Biologics (NASDAQ:ADMA) show a mix of bullish to bearish sentiments, with a recent trend towards more bullish projections. The average 12-month price target is now $6.75, up from $6.00, indicating a positive outlook. Key financial indicators reveal strong revenue growth, profitability, and financial health, despite a high debt-to-equity ratio. The company specializes in plasma-derived biologics for immunodeficient patients.
February 29, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics has received mixed analyst ratings but shows a positive trend with an updated average price target of $6.75. Strong financial indicators suggest a robust outlook.
The increase in the average price target to $6.75 from $6.00, along with strong revenue growth and profitability, suggests a positive short-term impact on ADMA's stock price. The bullish sentiment among analysts, despite some bearish views, further supports the potential for stock price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100